KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $178.0 million.

  • Pfizer's Gains from Investment Securities fell 9438.84% to $178.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 billion, marking a year-over-year increase of 620.83%. This contributed to the annual value of $3.6 billion for FY2024, which is 323.6% up from last year.
  • According to the latest figures from Q3 2025, Pfizer's Gains from Investment Securities is $178.0 million, which was down 9438.84% from $3.8 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's Gains from Investment Securities ranged from a high of $4.9 billion in Q4 2022 and a low of -$815.0 million during Q2 2022
  • Over the past 5 years, Pfizer's median Gains from Investment Securities value was $1.3 billion (recorded in 2023), while the average stood at $1.6 billion.
  • In the last 5 years, Pfizer's Gains from Investment Securities plummeted by 30685.28% in 2022 and then soared by 25963.72% in 2024.
  • Over the past 5 years, Pfizer's Gains from Investment Securities (Quarter) stood at $2.9 billion in 2021, then surged by 67.14% to $4.9 billion in 2022, then crashed by 88.11% to $585.0 million in 2023, then surged by 442.22% to $3.2 billion in 2024, then tumbled by 94.39% to $178.0 million in 2025.
  • Its Gains from Investment Securities was $178.0 million in Q3 2025, compared to $3.8 billion in Q2 2025 and -$300.0 million in Q1 2025.